These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7596480)

  • 21. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
    Fabianowska-Majewska K; Wyczechowska D
    Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
    Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
    J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
    Kopadze T; Döbert M; Leussink VI; Dehmel T; Kieseier BC
    Eur J Neurol; 2009 Mar; 16(3):409-12. PubMed ID: 19175384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
    Giovannoni G
    Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
    N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients.
    Grieb P; Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):323-7. PubMed ID: 8744654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E; Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1716-20. PubMed ID: 8643695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cladribine in treatment of chronic progressive multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Lancet; 1994 Jul; 344(8914):9-13. PubMed ID: 7912347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
    Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
    Biernacki T; Sandi D; Bencsik K; Vécsei L
    Mini Rev Med Chem; 2020; 20(4):269-285. PubMed ID: 31644403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS; Sipe JC; Koziol JA; Zyroff J; Beutler E
    Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
    Gummi R; Walsh RD; Ahmad B
    Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O
    Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.